SinoMab BioScience Limited — Capital/Financing Update 2021

Jun 22, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [29 x 43] intentionally omitted <==

==> picture [29 x 43] intentionally omitted <==

SinoMab BioScience Limited 中國抗體製藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 3681)

LAPSE OF PROPOSED ISSUE OF HK$100,000,000 CONVERTIBLE BONDS

Reference is made to the announcement (“ Announcement ”) of SinoMab BioScience Limited (中 國抗體製藥有限公司) (the “ Company ”) dated 22 December 2020 and the circular (“ Circular ”) of the Company dated 27 January 2021 in relation to the Subscription Agreement entered into between the Company and the Investor pursuant to which the Company agreed to issue and the Investor agreed to subscribe for the Convertible Bonds in an aggregate principal amount of HK$100,000,000. Unless the context otherwise requires, capitalised terms used in this announcement shall bear the same meanings as defined in the Circular.

Pursuant to the terms of the Subscription Agreement, as certain conditions precedent have not been fulfilled or waived as of the Long Stop Date, the Subscription Agreement has lapsed and the Convertible Bonds will not be issued under the Subscription Agreement.

The Directors are of the view that the lapse of the proposed issue of HK$100,000,000 Convertible Bonds does not have any material impact on the operations and financial position of the Group.

By Order of the Board SinoMab BioScience Limited Dr. Shui On LEUNG Executive Director, Chairman and Chief Executive Officer

Hong Kong, 22 June 2021

As at the date of this announcement, the executive Director is Dr. Shui On LEUNG, the nonexecutive Directors are Dr. Haigang CHEN, Mr. Xun DONG, Mr. Senlin LIU, Ms. Wenyi LIU, Mr. Huiyuan MA and Mr. Jing QIANG, and the independent non-executive Directors are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE and Mr. Dylan Carlo TINKER.